Arcutis Biotherapeutics Inc
NASDAQ:ARQT

Watchlist Manager
Arcutis Biotherapeutics Inc Logo
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Watchlist
Price: 14.62 USD 0.41% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Arcutis Biotherapeutics Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

-8.2
Current
-2.9
Median
4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-8.2
=
Enterprise Value
1.5B USD
/
EBIT
-181.9m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
US
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Average EV/EBIT: 21.5
Negative Multiple: -8.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 480.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.1
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.2
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -493.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.9
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-9.6
2-Years Forward
EV/EBIT
-13.8
3-Years Forward
EV/EBIT
239.7